Allied Market Research
Loading...
0
New
New
2021
Filgrastim Market

Filgrastim Market by Drug Type (Biologic and Biosimilar), Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2030

A03303
Pages: 193
Oct 2021 | 6150 Views
   
Author(s) : Smita Nerkar , Onkar Sumant
Tables: 118
Charts: 39
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Filgrastim Market

Request Now !

Filgrastim Market Statistics- 2030

Global filgrastim market was valued at $ 562.50 million in 2020 and is projected to reach $745.90 million by 2030 registering a CAGR of 2.80% from 2021 to 2030. Filgrastim is a recombinant DNA-derived granulocyte colony stimulating factor (G-CSF) that is commonly used to treat low blood neutrophils. It's also commonly employed in cases where lukapheresis is associated with an increase in white blood cells. Filgrastim has a number of side effects, including joint discomfort, chest pain, hair loss, and vomiting. 

Filgrastim is a recombinant version of the naturally occurring G-CSF that stimulates neutrophil production. It was licensed for the treatment of low blood neutrophils in the U.S. in 1991. The World Health Organization (WHO) declared Filgrastim in the List of Essential Medicines as safe and most effective medicine. Filgrastim was first discovered by Amgen, Inc. and sold under the brand name Neupogen. Large number of biosimilar companies are engaged in the manufacture and marketing of Filgrastim across the world. Filgrastim costs around $200 in the U.S, around 50 Euro in the UK, and $100 in developing countries.

Filgrastim-Market-2021-2030

Get more information on this report : Request Sample Pages

Factors such as increase in prevalence of various diseases and surge igeriatric population drives the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim, due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. Conversely, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.

Moreover, this medication is used to treat neutropenia, a condition that occurs after bone marrow transplantation and chemotherapy. It's been used to treat a variety of malignancies as a supportive therapy. In the recent decade, there has been a major growth in cancer prevention in industrialized countries, as well as government-led campaigns to raise awareness of early treatment. These reasons are projected to propel the worldwide Filgrastim market forward. Approved biosimilars such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper and readily available in developing countries, are expected to fuel the growth of the global Filgrastim market.

The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the globe. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. The filgrastim market size is expected to be negatively impacted by the COVID-19 situation. With the majority of countries suffering from the impact of COVID-19, many countries are looking for a way to cure COVID-19. The pandemic has had a serious and disruptive effect on oncology clinical trials and treatment, with both immediate and delayed consequences. According to a study conducted by the Cancer Research UK in July 2020, one in three cancer patients have confirmed that their treatment has been impacted by the effects of COVID-19. The short-term effects include staff and resources being reassigned to deal with COVID patients. In the longer term, trials testing treatments for COVID-19 have been ordered. A sharp reduction in recruitment to ongoing trials and a delay in the planned launch of new oncology studies is expected to negatively impact the filgrastim market.

Filgrastim Market Segmentation  

The global filgrastim market is segmented on the basis of drug type, distribution channel, indication and region. On the basis of drug type, it is further classified into biologic and biosimilar. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Based on indication, it is categorized into chemotherapy induced neutropenia, chronic neutropenia and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Filgrastim Market
By Drug Type

Your browser does not support the canvas element.

Biosimilar segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Segment Review

By drug type, the biosimilars segment is expected to expand at a higher growth rate due to low cost and easy availability in developing countries. Furthermore, ongoing biosimilars research and strong pipeline drugs are expected to boost the growth of the global market during the forecast period.

Based on distribution channel, the global filgrastim market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies. High demand for filgrastim in hospitals across the globe is projected to propel the hospital pharmacies segment from 2020 to 2030.

Filgrastim Market
By Indication

Your browser does not support the canvas element.

Reusable segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of the North America Filgrastim Market  

Europe is projected to account for a major share of the global filgrastim market during the forecast period. The market in the region is anticipated to grow in the future, owing to developed health care infrastructure and favorable reimbursement policies, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in Europe.

The key market players profiled in the report include Abbott Laboratories, Amgen, Apotex, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Kirin Holding (Kyowa Kirin), Novartis, Pfizer, Teva Pharmaceutical Industries Ltd. and Toksöz Group (Arven).

Filgrastim Market
By Region

2030
Europe 
North America
Asia-pacific
Lamea

North America is expected to experience growth at the highest rate, registering a CAGR of 3.20% during the forecast period.

Get more information on this report : Request Sample Pages

Filgrastim Market Research Study Key Benefits

  • The study provides an in-depth analysis of the global filgrastim market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of filgrastim used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments

By Drug Type

  • Biologic
  • Biosimilar

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Indication

  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Leading Players of Filgrastim Market

  • Abbott Laboratories 
  • Amgen 
  • Apotex 
  • Cadila Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Kirin Holding (Kyowa Kirin)
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries Ltd.
  • Toksöz Group
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Surge in geriatric population
3.5.1.2.Rise in demand for biosimilars in the treatment of neutropenia
3.5.1.3.Pharmaceutical companies are shifting toward biosimilar drug development

3.5.2.Restraints

3.5.2.1.Complexities in manufacturing of biosimilar
3.5.2.2.Increase in use of pegfilgrastim biologic

3.5.3.Opportunities

3.5.3.1.Increase in player-adopted strategies
3.5.3.2.Increase in awareness related to filgrastim

3.5.4.Impact analysis

3.6.COVID-19 Impact analysis on the filgrastim market

CHAPTER 4:FILGRASTIM MARKET, BY DRUG TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Biologic

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region

4.2.2.1.Market size and forecast for biologic by distribution channel

4.2.3.Market analysis, by country

4.3.Biosimilar

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast

4.3.2.1.Market size and forecast for biosimilar by distribution channel

4.3.3.Market analysis, by country

CHAPTER 5:FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacies

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Retail pharmacies

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.Online pharmacies

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

CHAPTER 6:FILGRASTIM MARKET, BY INDICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Chemotherapy induced Netropenia

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Chronic neutropenia

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Others

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:FILGRASTIM MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S. filgrastim market
7.2.2.2.U.S. filgrastim market, by drug type
7.2.2.3.U.S. filgrastim market, by distribution channel
7.2.2.4.U.S. filgrastim market, by indication
7.2.2.5.Canada filgrastim market
7.2.2.6.Canada filgrastim market, by drug type
7.2.2.7.Canada filgrastim market, by distribution channel
7.2.2.8.Canada filgrastim market, by indication
7.2.2.9.Mexico filgrastim market
7.2.2.10.Mexico filgrastim market, by drug type
7.2.2.11.Mexico filgrastim market, by distribution channel
7.2.2.12.Mexico filgrastim market, by indication

7.2.3.North America market size and forecast, by drug type
7.2.4.North America market size and forecast, by distribution channel
7.2.5.North America market size and forecast, by indication

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany filgrastim market
7.3.2.2.Germany filgrastim market, by drug type
7.3.2.3.Germany filgrastim market, by distribution channel
7.3.2.4.Germany filgrastim market, by indication
7.3.2.5.France filgrastim market
7.3.2.6.France filgrastim market, by drug type
7.3.2.7.France filgrastim market, by distribution channel
7.3.2.8.France filgrastim market, by indication
7.3.2.9.UK filgrastim market
7.3.2.10.UK filgrastim market, by drug type
7.3.2.11.UK filgrastim market, by distribution channel
7.3.2.12.UK filgrastim market, by indication
7.3.2.13.Italy filgrastim market
7.3.2.14.Italy filgrastim market, by drug type
7.3.2.15.Italy filgrastim market, by distribution channel
7.3.2.16.Italy filgrastim market, by indication
7.3.2.17.Spain filgrastim market
7.3.2.18.Spain filgrastim market, by drug type
7.3.2.19.Spain filgrastim market, by distribution channel
7.3.2.20.Spain filgrastim market, by indication
7.3.2.21.Rest of Europe filgrastim market
7.3.2.22.Rest of Europe filgrastim market, by drug type
7.3.2.23.Rest of Europe Filgrastim market, by distribution channel
7.3.2.24.Rest of Europe Filgrastim market, by indication

7.3.3.Europe market size and forecast, by drug type
7.3.4.Europe market size and forecast, by distribution channel
7.3.5.Europe market size and forecast, by indication

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan Filgrastim market
7.4.2.2.Japan Filgrastim market, by drug type
7.4.2.3.Japan Filgrastim market, by distribution channel
7.4.2.4.Japan Filgrastim market, by indication
7.4.2.5.China Filgrastim market
7.4.2.6.China Filgrastim market, by drug type
7.4.2.7.China filgrastim market, by distribution channel
7.4.2.8.China filgrastim market, by indication
7.4.2.9.Australia filgrastim market
7.4.2.10.Australia filgrastim market, by drug type
7.4.2.11.Australia filgrastim market, by distribution channel
7.4.2.12.Australia filgrastim market, by indication
7.4.2.13.India filgrastim market
7.4.2.14.India filgrastim market, by drug type
7.4.2.15.India filgrastim market, by distribution channel
7.4.2.16.India filgrastim market, by indication
7.4.2.17.South Korea filgrastim market
7.4.2.18.South Korea filgrastim market, by drug type
7.4.2.19.South Korea filgrastim market, by distribution channel
7.4.2.20.South Korea filgrastim market, by indication
7.4.2.21.Rest of Asia-Pacific filgrastim market
7.4.2.22.Rest of Asia-Pacific filgrastim market, by drug type
7.4.2.23.Rest of Asia-Pacific filgrastim market, by distribution channel
7.4.2.24.Rest of Asia-Pacific filgrastim market, by indication

7.4.3.Asia-Pacific market size and forecast, by drug type
7.4.4.Asia-Pacific market size and forecast, by distribution channel
7.4.5.Asia-Pacific market size and forecast, by indication

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil filgrastim market
7.5.2.2.Brazil filgrastim market, by drug type
7.5.2.3.Brazil filgrastim market, by distribution channel
7.5.2.4.Brazil filgrastim market, by indication
7.5.2.5.Saudi Arabia filgrastim market
7.5.2.6.Saudi Arabia filgrastim market, by drug type
7.5.2.7.Saudi Arabia filgrastim market, by distribution channel
7.5.2.8.Saudi Arabia filgrastim market, by indication
7.5.2.9.South Africa filgrastim market
7.5.2.10.South Africa filgrastim market, by drug type
7.5.2.11.South Africa filgrastim market, by distribution channel
7.5.2.12.South Africa filgrastim market, by indication
7.5.2.13.Rest of LAMEA filgrastim market
7.5.2.14.Rest of LAMEA filgrastim market, by drug type
7.5.2.15.Rest of LAMEA filgrastim market, by distribution channel
7.5.2.16.Rest of LAMEA filgrastim market, by indication

7.5.3.LAMEA market size and forecast, by drug type
7.5.4.LAMEA market size and forecast, by distribution channel
7.5.5.LAMEA market size and forecast, by indication

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.AMGEN INC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.APOTEX INC.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.DR. REDDY’S LABORATORIES LIMITED

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.KIRIN HOLDINGS

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.NOVARTIS AG

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Novartis offers the following products:
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.PFIZER INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.TOKSÖZ GROUP.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio

8.10.ZYDUS CADILLA

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 02.FILGRASTIM MARKET FOR BIOLOGIC, BY REGION, 2020-2030 ($MILLION)
TABLE 03.BIOLOGIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 04.FILGRASTIM MARKET FOR BIOSIMILAR, BY REGION, 2020-2030 ($MILLION)
TABLE 05.BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 06.FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 07.FILGRASTIM MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 08.FILGRASTIM MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 09.FILGRATIM MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 10.FILGRASTIM MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 11.FILGRASTIM MARKET FOR CHEMOTHERAPY INDUCED NETROPENIA, BY REGION, 2020-2030 ($MILLION)
TABLE 12.FILGRASTIM MARKET FOR CHRONIC NEUTROPENIA, BY REGION, 2020-2030 ($MILLION)
TABLE 13.FILGRASTIM MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 14.FILGRASTIM MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15.NORTH AMERICA FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 16.U.S. FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 17.U.S. FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 18.U.S. FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 19.CANADA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 20.CANADA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 21.CANADA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 22.MEXICO FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 23.MEXICO FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 24.MEXICO FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 25.NORTH AMERICA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 26.NORTH AMERICA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 27.NORTH AMERICA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 28.EUROPE FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 29.GERMANY FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 30.GERMANY FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 31.GERMANY FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 32.FRANCE FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 33.FRANCE FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 34.FRANCE FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 35.UK FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 36.UK FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 37.UK FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 38.ITALY FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 39.ITALY FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 40.ITALY FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 41.SPAIN FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 42.SPAIN FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 43.SPAIN FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 44.REST OF EUROPE FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 45.REST OF EUROPE FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 46.REST OF EUROPE FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 47.EUROPE FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 48.EUROPE FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 49.EUROPE FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 50.ASIA-PACIFIC FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 51.JAPAN FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 52.JAPAN FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 53.JAPAN FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 54.CHINA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 55.CHINA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 56.CHINA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 57.AUSTRALIA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 58.AUSTRALIA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 59.AUSTRALIA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 60.INDIA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 61.INDIA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 62.INDIA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 63.SOUTH KOREA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 64.SOUTH KOREA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 65.SOUTH KOREAFILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 66.REST OF ASIA-PACIFIC FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 67.REST OF ASIA-PACIFIC FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 68.REST OF ASIA-PACIFIC FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 69.ASIA-PACIFIC FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 70.ASIA-PACIFIC FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 71.ASIA-PACIFIC FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 72.LAMEA FILGRASTIM MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 73.BRAZIL FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 74.BRAZIL FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 75.BRAZIL FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 76.SAUDI ARABIA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 77.SAUDI ARABIA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 78.SAUDI ARABIA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 79.SOUTH AFRICA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 80.SOUTH AFRICA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 81.SOUTH AFRICA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 82.REST OF LAMEA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 83.REST OF LAMEA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 84.REST OF LAMEA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 85.LAMEA FILGRASTIM MARKET, BY DRUG TYPE, 2020-2030
TABLE 86.LAMEA FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 87.LAMEA FILGRASTIM MARKET, BY INDICATION, 2020-2030
TABLE 88.ABBOTT: COMPANY SNAPSHOT
TABLE 89.ABBOTT: OPERATING SEGMENTS
TABLE 90.ABBOTT: PRODUCT PORTFOLIO
TABLE 91.AMGEN: COMPANY SNAPSHOT
TABLE 92.AMGEN: OPERATING SEGMENT
TABLE 93.AMGEN: PRODUCT PORTFOLIO
TABLE 94.APOTEX: COMPANY SNAPSHOT
TABLE 95.APOTEX: OPERATING SEGMENTS
TABLE 96.APOTEX: PRODUCT PORTFOLIO
TABLE 97.REDDY: COMPANY SNAPSHOT
TABLE 98.REDDY: OPERATING BUSINESS SEGMENTS
TABLE 99.REDDY: PRODUCT PORTFOLIO
TABLE 100.KIRIN: COMPANY SNAPSHOT
TABLE 101.KIRIN: PRODUCT SEGMENTS
TABLE 102.KIRIN: PRODUCT PORTFOLIO
TABLE 103.NOVARTIS: COMPANY SNAPSHOT
TABLE 104.NOVARTIS: OPERATING SEGMENTS
TABLE 105.NOVARTIS: PRODUCT PORTFOLIO
TABLE 106.NOVARTIS: KEY DEVELOPMENTS
TABLE 107.PFIZER: COMPANY SNAPSHOT
TABLE 108.PFIZER: OPERATING SEGMENTS
TABLE 109.PFIZER: PRODUCT PORTFOLIO
TABLE 110.TEVA: COMPANY SNAPSHOT
TABLE 111.TEVA: OPERATING SEGMENTS
TABLE 112.TEVA: PRODUCT PORTFOLIO
TABLE 113.TOKSÖZ: COMPANY SNAPSHOT
TABLE 114.TOKSÖZ: OPERATING SEGMENTS
TABLE 115.TOKSÖZ: PRODUCT PORTFOLIO
TABLE 116.ZYDUS: COMPANY SNAPSHOT
TABLE 117.ZYDUS: OPERATING SEGMENTS
TABLE 118.ZYDUS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.FILGRASTIM MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR BIOLOGIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR BIOSIMILAR, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF FILGRATIM MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR CHEMOTHERAPY INDUCED NETROPENIA, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR CHRONIC NEUTROPENIA,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF FILGRASTIM MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 21.AMGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.AMGEN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 23.REDDY: NET SALES, 2019–2021 ($MILLION)
FIGURE 24.REDDY: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 25.REDDY: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 26.KIRIN: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.KIRIN: REVENUE SHARE BY SEGMENT, 2020(%)
FIGURE 28.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.PFIZER NET SALES, 2019–2020 ($MILLION)
FIGURE 32.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 34.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.TEVA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.ZYDUS NET SALES, 2019–2020 ($MILLION)
FIGURE 38.ZYDUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.ZYDUS: REVENUE SHARE BY GEOGRAPHY, 2020 (%)

 
 

Filgrastim market growth includes increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. On the other hand, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.

Europe is projected to account for a major share of the global filgrastim market during the forecast period. The market in the region is anticipated to witness growth in the future, owing to developed healthcare infrastructure and favorable reimbursement policies, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in Europe. Furthermore, increase in number of cancer patients, particularly in developing countries such as China and India, is one of the key factors expected to propel the global filgrastim market during the forecast period.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Filgrastim market is $562.5 million in 2020.

A. The forcast period for Filgrastim market is 2021 to 2030

A. The market value of Filgrastim market in 2021 is $582.2 million.

A. The base year is 2020 in Filgrastim market

A. Top companies such asAbbott Laboratories, Amgen, Apotex, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Kirin Holding (Kyowa Kirin), Novartis, Pfizer, Teva Pharmaceutical Industries Ltd and Toksöz Group (Arven) held a high market position in 2020.

A. Biosimilars segment is expected to expand at a higher growth rate due to low cost and easy availability in developing countries. Furthermore, ongoing biosimilars research and strong pipeline drugs are likely expected to boost the growth of the global market during the forecast period.

A. Increase in prevalence of various diseases and surge in geriatric population drives the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim, due to its cost effectiveness is anticipated to boost the growth of this market

A. Europe is projected to account for a major share of the global filgrastim market during the forecast period. The market in the region is anticipated to grow in the future, owing to developed health care infrastructure and favorable reimbursement policies, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in North America.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Filgrastim Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers